Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birabresib (MK-8628) in Advanced Solid Tumors
NCT02698176Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of birabresib in NUT carcinoma (NMC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 1 more (4 arms), sponsored by Merck & Co. Primary endpoint: Dose Limiting Toxicity. Started May 2016; status: terminated.
02
Drugs
birabresib
03
Conditions
NUT carcinoma (NMC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02698176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698176.